Company intelligence / Profile preview

Hawkeye Systems

United Kingdom

Ownership: Private
Development stage: Other

Overview

QF-Pro® technology demonstrated clinical value in predicting response to anti-PD-1/PD-L1 therapies in lung cancer patients, outperforming PD-L1 TPS score by tripling response rates and doubling survival in studies published in Journal of Clinical Oncology.[1]

Therapeutic areas: Oncology
Industry: Protein Biomarker Diagnostics

Partnerships

Francis Crick InstituteCancer Research UK

Beyond the preview

Go deeper on Hawkeye Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hawkeye Systems.

Explore the full profile